Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11633-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11633-1-AP, RRID:AB_2241834
- Product name
- ZMYND8 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated ZMYND8 antibody (Cat. #11633-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references ZMYND8 promotes the Warburg effect and tumorigenesis through c-Myc activation in pancreatic cancer.
Phase separation of ERCC6L2-CtIP regulates the extent of DNA end resection.
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
Basis of gene-specific transcription regulation by the Integrator complex.
Mesenchymal stem cells overexpressing XIST induce macrophage M2 polarization and improve neural stem cell homeostatic microenvironment, alleviating spinal cord injury.
KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability.
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.
Liu H, Zhao Z, Wu C, Chen J, He Z, Jiang K
Oncogene 2025 Sep;44(34):3083-3095
Oncogene 2025 Sep;44(34):3083-3095
Phase separation of ERCC6L2-CtIP regulates the extent of DNA end resection.
Yin Y, Lin J, Cai X, Nie R, Lin J, Li S, Xiang Z, Ling Y, Zhang Y, Zhou J, Chen J, Lin W, Duan J, Zheng X, Xie D, Cai M
Nature cell biology 2025 Oct;27(10):1771-1784
Nature cell biology 2025 Oct;27(10):1771-1784
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
Bharti R, Dey G, Khan D, Myers A, Huffman OG, Saygin C, Braley C, Richards E, Sangwan N, Willard B, Lathia JD, Fox PL, Lin F, Jha BK, Brown JM, Yu JS, Dwidar M, Joehlin-Price A, Vargas R, Michener CM, Longworth MS, Reizes O
Molecular cancer 2024 Jun 10;23(1):121
Molecular cancer 2024 Jun 10;23(1):121
Basis of gene-specific transcription regulation by the Integrator complex.
Sabath K, Nabih A, Arnold C, Moussa R, Domjan D, Zaugg JB, Jonas S
Molecular cell 2024 Jul 11;84(13):2525-2541.e12
Molecular cell 2024 Jul 11;84(13):2525-2541.e12
Mesenchymal stem cells overexpressing XIST induce macrophage M2 polarization and improve neural stem cell homeostatic microenvironment, alleviating spinal cord injury.
Zhu D, Peng T, Zhang Z, Guo S, Su Y, Zhang K, Wang J, Liu C
Journal of tissue engineering 2024 Jan-Dec;15:20417314231219280
Journal of tissue engineering 2024 Jan-Dec;15:20417314231219280
KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y, Fan J, Xie C, Yan L, Song X, Zhang N, Lin Y, Xiong J, Zhang W, Liu Y, Wei L, Li Y, Chen S, Liang K, Li F
Cancer research 2024 Apr 15;84(8):1252-1269
Cancer research 2024 Apr 15;84(8):1252-1269
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability.
Pan Q, Zhong S, Wang H, Wang X, Li N, Li Y, Zhang G, Yuan H, Lian Y, Chen Q, Han Y, Guo J, Liu Q, Qiu T, Jiang J, Li Q, Tan M, Yin H, Peng J, Xiao Y, Qin J
Molecular cell 2021 Jul 1;81(13):2736-2751.e8
Molecular cell 2021 Jul 1;81(13):2736-2751.e8
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, Jiang YZ
Molecular cancer 2020 May 11;19(1):87
Molecular cancer 2020 May 11;19(1):87
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.
Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu S, Yu KD, Shao ZM
Science advances 2019 Mar;5(3):eaat9820
Science advances 2019 Mar;5(3):eaat9820
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ZMYND8 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ZMYND8. This antibody recognizes human, mouse, rat antigen. The ZMYND8 antibody has been validated for the following applications: ELISA, IHC analysis.
